Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Suspended 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Leukemia, Myeloid, Acute 25Advanced Solid Tumors 18Breast Neoplasms 12Myelodysplastic Syndromes 11Neoplasms 10Advanced Solid Tumor 10Prostatic Neoplasms 9Solid Tumor 7Neoplasm Metastasis 7Multiple Myeloma 7Recurrence 6Carcinoma, Non-Small-Cell Lung 6Pancreatic Neoplasms 5Colorectal Neoplasms 5Stomach Neoplasms 4Small Cell Lung Carcinoma 4Melanoma 4Leukemia, Myelomonocytic, Chronic 4Leukemia 4Solid Tumors 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Lung Neoplasms 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Primary Myelofibrosis 2Nasopharyngeal Carcinoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2

Interventions

Irinotecan 2Injections 2vistusertib 1urelumab 1sapanisertib 1durvalumab 1danvatirsen 1ceralasertib 1cediranib 1atezolizumab 1ZD4054 1Topotecan 1Tiragolumab 1Rosuvastatin Calcium 1Radiotherapy 1Rabeprazole 1Metformin 1HM781-36B 1Furosemide 1Digoxin 1ATP Binding Cassette Transporter, Subfamily B, Member 1 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 13-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Advanced Solid Malignancies × Injections × Clear all
NCT07368478 2026-01-26

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies

Biocity Biopharmaceutics Co., Ltd.

Phase 1 Recruiting
180 enrolled

Advanced Solid Malignancies

NCT06388902 2025-11-21

A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies

BioRay Pharmaceutical Co., Ltd.

Phase 1 Suspended
120 enrolled

Advanced Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡